News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
184,132 Results
Type
Article (11401)
Company Profile (94)
Press Release (172637)
Section
Business (53175)
Career Advice (133)
Deals (8346)
Drug Delivery (17)
Drug Development (37074)
Employer Resources (18)
FDA (4601)
Job Trends (4746)
News (99725)
Policy (6925)
Tag
2024 BioCapital Digital (3)
2024 BioForest Digital (2)
2024 BioMidwest Digital (2)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (1)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (1)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (1)
2024 Pharm Country Standard (4)
2025 Lone Star Bio Digital (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (681)
Academic (1)
Adcomms (12)
Allergies (69)
Alliances (15404)
ALS (26)
Alzheimer's disease (334)
Antibody-drug conjugate (ADC) (89)
Approvals (4634)
Artificial intelligence (92)
Autoimmune disease (8)
Automation (3)
Bankruptcy (61)
Best Places to Work (4385)
BIOSECURE Act (1)
Biosimilars (55)
Biotechnology (80)
Bladder cancer (47)
Brain cancer (22)
Breast cancer (194)
Cancer (1511)
Cardiovascular disease (22)
Career advice (116)
Career pathing (3)
CAR-T (92)
Cell therapy (234)
Cervical cancer (10)
Clinical research (30095)
Collaboration (367)
Compensation (111)
Complete response letters (5)
COVID-19 (1025)
CRISPR (15)
C-suite (82)
Cystic fibrosis (10)
Data (960)
Decentralized trials (1)
Denatured (4)
Depression (5)
Diabetes (41)
Diagnostics (2190)
Digital health (4)
Diversity (1)
Diversity, equity & inclusion (6)
Drug discovery (48)
Drug pricing (15)
Drug shortages (2)
Duchenne muscular dystrophy (15)
Earnings (18506)
Editorial (9)
Employer branding (3)
Employer resources (19)
Events (33259)
Executive appointments (253)
FDA (4992)
Featured Employer (16)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (3)
Funding (215)
Gene editing (29)
Generative AI (8)
Gene therapy (78)
GLP-1 (155)
Government (870)
Grass and pollen (3)
Guidances (13)
Healthcare (5838)
Huntington's disease (4)
IgA nephropathy (18)
Immunology and inflammation (83)
Indications (18)
Infectious disease (1083)
Inflammatory bowel disease (70)
Inflation Reduction Act (6)
Influenza (18)
Intellectual property (24)
Interviews (17)
IPO (4298)
IRA (13)
Job creations (643)
Job search strategy (109)
Kidney cancer (10)
Labor market (2)
Layoffs (149)
Leadership (2)
Legal (689)
Liver cancer (48)
Lung cancer (227)
Lymphoma (86)
Management (5)
Manufacturing (58)
MASH (7)
Medical device (1210)
Medtech (1210)
Mergers & acquisitions (4198)
Metabolic disorders (90)
Multiple sclerosis (35)
NASH (1)
Neurodegenerative disease (19)
Neuropsychiatric disorders (5)
Neuroscience (482)
NextGen: Class of 2025 (1365)
Non-profit (819)
Northern California (981)
Now hiring (11)
Obesity (40)
Opinion (47)
Ovarian cancer (55)
Pain (9)
Pancreatic cancer (53)
Parkinson's disease (37)
Partnered (2)
Patents (49)
Patient recruitment (37)
Peanut (46)
People (17327)
Pharmaceutical (18)
Pharmacy benefit managers (2)
Phase I (11199)
Phase II (13021)
Phase III (9507)
Pipeline (430)
Podcasts (19)
Policy (21)
Postmarket research (765)
Preclinical (3901)
Press Release (21)
Prostate cancer (67)
Psychedelics (4)
Radiopharmaceuticals (171)
Rare diseases (81)
Real estate (1051)
Recruiting (7)
Regulatory (6067)
Reports (11)
Research institute (1048)
Resumes & cover letters (14)
RSV (22)
Schizophrenia (21)
Series A (48)
Series B (15)
Service/supplier (1)
Sickle cell disease (16)
Southern California (899)
Special edition (1)
Sponsored (7)
Startups (1049)
State (1)
Stomach cancer (8)
Supply chain (10)
The Weekly (15)
United States (7427)
Vaccines (358)
Venture capitalists (15)
Webinars (3)
Weight loss (24)
Women's health (3)
Date
Today (66)
Last 7 days (314)
Last 30 days (1159)
Last 365 days (14128)
2025 (2218)
2024 (14356)
2023 (15967)
2022 (19738)
2021 (19748)
2020 (16817)
2019 (12069)
2018 (8963)
2017 (10134)
2016 (9074)
2015 (10049)
2014 (6763)
2013 (4787)
2012 (4962)
2011 (5103)
2010 (4719)
Location
Africa (127)
Alabama (25)
Alaska (1)
Arizona (31)
Arkansas (4)
Asia (13794)
Australia (2149)
California (2187)
Canada (578)
China (249)
Colorado (72)
Connecticut (82)
Delaware (87)
Europe (30006)
Florida (252)
Georgia (39)
Idaho (13)
Illinois (155)
India (9)
Indiana (65)
Iowa (1)
Japan (80)
Kansas (15)
Kentucky (11)
Maine (6)
Maryland (298)
Massachusetts (1663)
Michigan (20)
Minnesota (71)
Missouri (10)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (8)
New Jersey (688)
New Mexico (5)
New York (529)
North Carolina (212)
North Dakota (6)
Northern California (981)
Ohio (52)
Oklahoma (1)
Oregon (9)
Pennsylvania (360)
Rhode Island (6)
South America (160)
South Carolina (2)
Southern California (899)
Tennessee (16)
Texas (323)
Utah (40)
Virginia (24)
Washington D.C. (11)
Washington State (226)
Wisconsin (15)
184,132 Results for "kineta immuno oncology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
The Search for the Next Keytruda: Immuno-Oncology’s Next Play
More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a crossroads, with experts highlighting novel targets, combinations and pre-emptive immunization as the next wave for IO.
March 3, 2025
·
7 min read
·
Heather McKenzie
Collaboration
Incyte Backs Out of Immuno-Oncology Pact With Agenus
The partnership dates back to 2015, when Incyte paid $60 million upfront for access to four checkpoint programs, including TIM-3, LAG-3, OX40 and GITR.
February 12, 2025
·
2 min read
·
Tristan Manalac
Drug Development
Kineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023
Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present at the Oxford Global Immuno US 2023, to be held on October 12-13, 2023 in San Diego, CA.
October 9, 2023
·
1 min read
Press Releases
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications
February 27, 2025
·
13 min read
Press Releases
Ellipses In-Licences First in Class Novel Immuno-Oncology Agent With Potential as a Next Generation Checkpoint Inhibitor
February 11, 2025
·
3 min read
Press Releases
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
December 12, 2024
·
19 min read
Drug Development
Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1
October 2, 2024
·
7 min read
Press Releases
Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference
February 10, 2025
·
1 min read
BioForest
Kineta to Host Key Opinion Leader Event on KVA12123: VISTA as an Immuno-Oncology Target
Kineta, Inc. announced today it will host a virtual Key Opinion Leader (KOL) event on VISTA as an immuno-oncology target on Monday, March 20, 2023 at 10:00 AM ET.
March 6, 2023
·
6 min read
Business
Kineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts to its Scientific Advisory Board
Kineta, Inc. announced today the appointment of Myriam Chalabi, M.D. and Evan Ya-Wen Yu, M.D. to the company’s immuno-oncology focused Scientific Advisory Board (SAB).
March 1, 2023
·
7 min read
1 of 18,414
Next
